Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Hard-to-Treat lymphoma: phase 3 trial launches

NCT ID NCT07011056

Disease control Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tests a new drug called purinostat mesylate against an existing drug, selinexor, in 390 adults with relapsed or refractory diffuse large B-cell lymphoma. Participants receive either purinostat mesylate by infusion or selinexor by mouth. The study aims to see which drug works better at shrinking tumors and improving survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
purinostat mesylate
What this could lead to
If it works, this could offer a new treatment option for people with hard-to-treat diffuse large B-cell lymphoma who have not responded to other therapies.
What could go wrong
This is a phase 3 trial, but it compares a new drug to another existing drug, so the benefit may be modest. Side effects are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 390 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years, no gender restrictions; 2. Histologically-confirmed DLBCL, Participants must have relapsed or failed to respond to at least two lines of prior systemic therapy (2-5 lines); 3. Participants must have measurable disease; 4. ECOG≤2; 5. Adequate organ function Exclusion Criteria: 1. Pregnancy or breastfeeding; 2. Previous history of transplantation; 3. Double/Triple Hit B cell lymphoma; 4. Patient with known active infection, or reactivation of a latent infection; 5. Any serious diseases that investigator deems inappropriate to participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent and refractory diffuse large B-cell lymphoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma Recurrence relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrent and refractory diffuse large B-cell lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • West China Hospital Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610200, China